Teva Acquires Rights To Oncology Biosimilar Candidates
Zacks Investment Research | Oct 10, 2016 09:25PM ET
Generic drug maker Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has entered into an exclusive biosimilar commercial partnership with Korean biopharmaceutical company Celltrion, Inc and its distribution partner Celltrion Healthcare.
Per the deal, Teva gets exclusive rights to commercialize two of Celltrion’s phase III biosimilar monoclonal antibodies (mAbs) biosimilar candidates – CT-P10 and CT-P6 – in the U.S. and Canada, pending regulatory approvals. Celltrion will, however, be responsible to finish off their clinical development and regulatory formalities.
CT-P10 is a proposed mAb biosimilar to Roche Holding (SIX:ROG) AG’s (OTC:RHHBY) drug Rituxan (rituximab) which is approved to treat non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia, rheumatoid arthritis, Wegener’s Granulomatosis and Microscopic Polyangiitis. CT-P6, on the other hand, is a proposed mAb biosimilar to Roche’s key breast cancer drug Herceptin (trastuzumab).
Both the candidates have met their primary endpoints in the respective late-stage phase III studies. While CT-P10 is under review in the EU, CT-P6 is planned to be submitted for review to the European Medicines Agency (EMA) this quarter.
TEVA PHARM ADR Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.